SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Voices Concern over IST Provisions in Chemical-Site Security Measures


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) criticized the Secure Chemicals Facilities Act, which would require chemical facilities to use inherently safer technology (IST) as part of chemical-site security measures. The bill, which is cosponsored by Sen. Frank Lautenberg (D–NJ), was recently reintroduced as Congress considers whether to extend the Chemical Facility Anti-Terrorism Standards (CFAT), )which include current federal chemical-site security provisions.

CFATS are risk-based performance standards designed to ensure the security of US chemical facilities. They require covered chemical facilities to prepare security vulnerability assessments and to develop and implement site-security plans, which include measures that satisfy the identified risk-based performance standards. Although SOCMA supports CFATS, it opposes the use of IST in those provisions. IST is a conceptual framework that covers chemical-processing procedures, equipment, protection, and when feasible, the use of safer substances.

“While four previous bills have been introduced this Congress extending the current security rules, Lautenberg has chosen to advocate for costly and unnecessary adjustments to standards that are widely believed to be comprehensive and accountable,” said Bill Allmond, SOCMA’s vice-president of government relations, in an Apr. 1, 2011 SOCMA press release. In testimony before the House Energy and Commerce Committee's Subcommittee on Environment and the Economy, on Mar. 31, 2011, Allmond said that  “[IST] is an elegant concept, but the reality is almost never that simple. A reduction in hazard will reduce overall risk if, and only if, that hazard is not displaced to another time or location, or results in the creation of some new hazard.” He noted that no agreed-upon methodology exists to measure whether one process is inherently safer than another process. “For all these reasons, the world’s foremost experts in IST and chemical engineering have consistently recommended against regulating inherent safety for security purposes,” he said.

SOCMA supports other legislation (HR 908) that would extend the current authority of CFATS to the Department of Homeland Security CFATS through 2017. “The need for annual reauthorization of the program has created uncertainty for facilities regulated by CFATS,” said Allmond in his written testimony. “Without the assurance of a long-term authorization of these regulations, companies run a risk of investing in costly activities today that might not satisfy regulatory standards tomorrow.”

SOCMA will continue to work with the House and Senate towards the passage of a long-term authorization of CFATS.  On Apr. 13,2011, SOCMA members willy take their message directly to Congress and discuss their position with lawmakers and their staff during SOCMA Connect’s Fourth Annual Washington Fly-in.

See related stories:
SOCMA Urges Congressional Action on Chemical-Site Security Standards (ePT)

SOCMA Voices Concern over Chemical-Site Security Bill (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here